Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L. Goel R, et al. Among authors: stafford s. Invest New Drugs. 2005 Jan;23(1):63-71. doi: 10.1023/B:DRUG.0000047107.35764.d9. Invest New Drugs. 2005. PMID: 15528982 Clinical Trial.
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. Goss G, et al. Among authors: stafford s. Invest New Drugs. 2005 Mar;23(2):147-55. doi: 10.1007/s10637-005-5860-y. Invest New Drugs. 2005. PMID: 15744591 Clinical Trial.
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.
Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Agarwal V, Humphrey R, Seymour AL. Hirte H, et al. Among authors: stafford s. Invest New Drugs. 2005 Oct;23(5):437-43. doi: 10.1007/s10637-005-2903-3. Invest New Drugs. 2005. PMID: 16133795 Clinical Trial.
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH, Petersen IA, Shives TC, Mahoney MR, Rock MG, Haddock MG, Sim FH, Maples WJ, O'Connor MI, Gunderson LL, Foo ML, Pritchard DJ, Buckner JC, Stafford SL. Edmonson JH, et al. Cancer. 2002 Feb 1;94(3):786-92. doi: 10.1002/cncr.10259. Cancer. 2002. PMID: 11857314 Free article. Clinical Trial.
The clinical case for proton beam therapy.
Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, Brent CR, Kruse JJ, Ezzell GA, Herman MG, Gunderson LL, Erlichman C, Diasio RB. Foote RL, et al. Among authors: stafford sl. Radiat Oncol. 2012 Oct 22;7:174. doi: 10.1186/1748-717X-7-174. Radiat Oncol. 2012. PMID: 23083010 Free PMC article. Review.
291 results